Search results
Results from the WOW.Com Content Network
Lawsuits over Xarelto began piling up in 2014 and the companies had so far won all six trials over Xarelto's alleged bleeding risk. Bayer, J&J settle thousands of U.S. Xarelto lawsuits for $775 ...
The group has seen recent successes in battling these lawsuits. The exclusivity for Bayer’s blood-clot medication, Xarelto, its bestselling drug, is set to expire in 2026, allowing competitors ...
Bayer's patent covering its best-selling blood thinner Xarelto is invalid, London's High Court ruled on Friday in a blow to the German drugmaker. The company's blockbuster Xarelto drug generated ...
In 2019, Bayer and Johnson & Johnson (who market Xarelto together) settled around 25,000 lawsuits on the blood thinning drug Xarelto (rivaroxaban) by agreeing to disburse $775 million (US) to federal and state plaintiffs who said the companies had not properly warned patients about possible fatal bleeding as a result of ingesting the drug ...
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...
Eliquis brought Bristol Myers about $8.52 billion in U.S. sales last year, while J&J recorded $2.36 billion in Xarelto sales. Eliquis is shared with Pfizer and Xarelto with Bayer, which were not ...
Bayer boss Werner Baumann's contract has been extended until 2024, in a show of support from the drugmaker's new chairman just months after the company agreed an $11 billion outline settlement of ...
In 2020, Bayer settled most of the then-pending Roundup cases for up to $9.6 billion but failed to get a settlement covering future cases. More than 50,000 claims remain pending.